Evofem Biosciences Inc

Change company Symbol lookup

Select an option...

EVFM Evofem Biosciences Inc

RNWWW ReNew Energy Global Equity Warrant Exp 23rd Aug 2026 *W EXP 08/23/2026

RVPH Reviva Pharmaceuticals Holdings, Inc.

TPR Tapestry Inc

BGRY Berkshire Grey Inc

BKNG Booking Holdings Inc

UHT Universal Health Realty Income Trust

BBVA Banco Bilbao Vizcaya Argentaria SA

RILY B Riley Financial Inc

WTS Watts Water Technologies Inc

Go

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. It is engaged in developing and commercializing products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). Its product, Phexxi vaginal gel, is a hormone-free, woman-controlled, on-demand prescription contraceptive gel for women. Its lead clinical program is evaluating Phexxi (using the investigational name EVO100) for the prevention of chlamydia and gonorrhea in women. EVO200 vaginal gel (EVO200), its investigational candidate for the reduction of recurrent bacterial vaginosis (BV), uses the same vaginal potential of hydrogen (pH) modulator platform as Phexxi. It also focuses on developing Multipurpose Prevention Technology (MPT) vaginal gel for indications, including the prevention of human immunodeficiency virus (HIV) in women through Orion Biotechnology Canada Ltd.